Regulatory Roundup, Week of November 19, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup, Week of November 19, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Pharmacopeial Convention (USP) has announced a new drug naming policy to take affect May 1, 2013. USP worked on the new policy with FDA and industry stakeholders to clarify naming practices for medicines and make them more consistent. According to USP, “the policy will apply prospectively to drug product and compounded preparation monographs that appear in USP’s compendia of public quality standards—the United States Pharmacopeia and National Formulary (USP–NF).”  For more information, visit USP’s website at http://uspgo.to/monograph-naming.

USP has also announced its “Fifth Bioassay Workshop,” which will be held on Dec. 4-5, 2012 at USP headquarters in Rockville, MD. The workshop will focus on the development, monitoring, and validation of bioassays. Visit USP's website for more information.

FDA has made available, Guidance on Q11 Development and Manufacture of Drug Substances. FDA intends the guidance to “harmonize the scientific and technical principals relating to the description and justification of the development and manufacturing process of drug substances….”  

Also released by FDA on November 19, 2012 is Guidance for Industry, Electronic Source Data in Clinical Investigations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here